1147PEfficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas

ConclusionsAnlotinib showed a high disease control rate in patients with RMSGCs. The toxicity was tolerable and manageable.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research